Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 650x65px
Organisation › Details

Ultimovacs (Group)

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine for use as monotherapy and as a platform for other immuno-oncology drugs which require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe and the USA. Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is privately held, mainly by Norwegian private investors/family offices. Ultimovacs has started preparations for a potential listing of the Company on the Oslo Stock Exchange and the aim is to complete the IPO during the first part of 2019. The main purpose of the IPO is to ensure financing of operations and core development projects for the next five years with intent to file for Marketing Authorisation of UV1. *

 

Period Start 2011-01-01 established
  Predecessor Oslo University Hospital
Products Industry cancer vaccine
  Industry 2 TET-platform™ technology
Person Person Arnesen, Øyvind Kongstun (Ultimovacs AS 201808 CEO)
     
Region Region Oslo
  Country Norway
  Street 64 Ullernchausséen
  City 0379 Oslo
    Address record changed: 2018-09-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Immuneed AB. (8/30/18). "Press Release: Ultimovacs Acquires the Immunotherapy Technology Business of Immuneed AB for NOK 50 Million".
     
   
Record changed: 2018-09-02

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

More documents for Ultimovacs (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px




» top